SVB Leerink Maintains Market Perform on Amedisys, Lowers Price Target to $85
SVB Leerink analyst Whit Mayo maintains Amedisys (NASDAQ:AMED) with a Market Perform and lowers the price target from $96 to $85.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 293 companies set new 52-week lows.
Amedisys Names Scott Ginn Acting Chief Operating Officer
Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice, personal care and high-acuity care, names Scott Ginn, Executive Vice President and Chief Financial Officer, its Acting Chief Operating
Reported Late Thursday, Amedisys Confirms Full Year Guidance
Today, the Board of Directors of Amedisys, Inc. (NASDAQ:AMED) announced a leadership change that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022,
Stephens & Co. Maintains Equal-Weight on Amedisys, Lowers Price Target to $106
Stephens & Co. analyst Scott Fidel maintains Amedisys (NASDAQ:AMED) with a Equal-Weight and lowers the price target from $122 to $106.
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 236 companies set new 52-week lows.
RBC Capital Maintains Outperform on Amedisys, Lowers Price Target to $139
RBC Capital analyst Frank Morgan maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $165 to $139.
Barclays Maintains Overweight on Amedisys, Lowers Price Target to $126
Barclays analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Overweight and lowers the price target from $154 to $126.
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers
UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also reported better-than-expected Q3 sales results.
Expert Ratings for Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings: